SARS-CoV-2 antibody kinetics in blood donors with a previously positive SARS-CoV-2 antibody test within a seroprevalence survey
| Autor: | Joschka Martin Bauer, Søren Thue Lillevang, Mette Bøegh Levring, Line D Rasmussen, Iben Skov Jensen, Anna Christine Nilsson, Jesper Rømhild Davidsen, Ulrik Sprogøe, Dorte Kinggaard Holm |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Male
Adult Reinfection/blood Coronavirus disease 2019 (COVID-19) Igm antibody Denmark Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19/blood Blood Donors Antibodies Viral medicine.disease_cause Severity of Illness Index SARS-CoV-2/immunology Persistence (computer science) lateral flow test Lateral flow test Young Adult Antibodies Viral/blood Seroepidemiologic Studies Virology antibody Immunoglobulin A/blood medicine Seroprevalence Humans Coronavirus biology business.industry SARS-CoV-2 COVID-19 Immunoglobulin M/blood Denmark/epidemiology Immunoglobulin A Blood Donors/statistics & numerical data Kinetics Infectious Diseases Immunoglobulin M Immunoglobulin G/blood Immunoglobulin G Reinfection Immunology biology.protein blood donors Female Antibody business |
| Zdroj: | Levring, M B, Holm, D K, Nilsson, A C, Bauer, J M, Jensen, I S, Davidsen, J R, Rasmussen, L D, Sprogøe, U & Lillevang, S T 2022, ' SARS-CoV-2 antibody kinetics in blood donors with a previously positive SARS-CoV-2 antibody test within a seroprevalence survey ', Journal of Medical Virology, vol. 94, no. 4, pp. 1711-1716 . https://doi.org/10.1002/jmv.27486 |
| DOI: | 10.1002/jmv.27486 |
| Popis: | The persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies is a matter of importance regarding the coronavirus disease 19 (COVID-19) pandemic. To observe antibody dynamics, 105 blood donors, positive for SARS-CoV-2 antibodies by a lateral flow test within a seroprevalence study, were included in this study. Thirty-nine (37%) of 105 the donors were confirmed positive by a total Ig Wantai enzyme-linked immunosorbent assay (ELISA). Three (8%) in this group of 39 reported severe and 26/39 (67%) mild to moderate COVID-19 symptoms. By further ELISA-testing, 33/39 (85%) donors were initially positive for IgG antibodies, 31/39 (79%) for IgA, and 32/39 (82%) for IgM, while 27/39 (69%) were positive for all three isotypes. Persistence of IgG, IgA, and IgM was observed in 73%, 79%, and 32% of donors, respectively, after 6–9 months of observation. For IgM antibodies, the decline in the proportion of positive donors was statistically significant (p = 0.002) during 12 months observation, for IgG only the decline at 3 months was statistically significant (p = 0.042). Four donors exhibited notable increases in antibody levels. In conclusion, persistent SARS-CoV-2 IgA antibodies and IgG antibodies at 6–9 months are present in approximately three of four individuals with previous mild to moderate COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|